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Evaluation of Intravenous Proton Pump Inhibitor Use:
Medication Use Evaluation
By: Larissa Hall, PharmD; Kellianne Boyle, PharmD; Deirdre Delea,
PharmD; Haley Goodwin, PharmD; Jessica Mercer, PharmD;
Jenna Scheffert, PharmD; Mickala Thompson, PharmD; Ashley Tyler,
PharmD; Kelli Garrison, PharmD, BCPS; Nicole Bohm, PharmD,
BCPS; Tanna Cooper, PharmD, BCPS
MUSC has established guidelines and a pre-printed clinician
order form to encourage the appropriate use of intravenous (IV)
pantoprazole in the adult population. The guidelines address appropriate and inappropriate indications for IV pantoprazole,
doses, duration, eligibility for
oral therapy, and alternative
choices. While all inpatient services are required to use the preprinted clinician order form, use
of IV pantoprazole is not restricted to any particular service.
Appropriate indications for use
of IV pantoprazole at MUSC are
listed in Table 1.
Evidence suggests that proton
pump inhibitor (PPI) continuous
infusions are more effective than
intermittent infusions in reduc-

ing the rate of rebleeding in endoscopically treated patients with
active non-variceal upper gastrointestinal bleeding (NVUGIB).
The possibility exists that patients
who require a continuous infusion
are inappropriately receiving a
PPI intermittent infusion. Additionally, patients are receiving IV
PPI therapy without an appropriate indication.
FDA-approved indications for the
use of IV pantoprazole include the
following: gastroesophageal reflux disease (GERD) associated
with erosive esophagitis (40 mg
daily) or pathological gastric
hypersecretion (80 mg every 8-12
hours).1 Additionally, consensus
recommendations for off-label use
of IV pantoprazole for NVUGIB
have previously been established.2

Table 1: Appropriate Indications for IV Pantoprazole Use
Definite or probable evidence of non-variceal upper gastrointestinal bleeding
(NVUGIB)
Documented bleed and/or treatment failure while on histamine-2 receptor antagonist
(H2RA) or sucralfate when oral therapy is not clinically feasible
Documented hypersecretory condition (e.g., Zollinger-Ellison syndrome or
idiopathic) when oral therapy is not clinically feasible
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It should be noted that IV PPIs are
merely adjunctive therapy for
high-risk patients (ie, those with
endoscopic evidence of active
bleeding, a visible vessel in an
ulcer bed, or a clot in an ulcer
bed) who have been treated endoscopically with hemostatic agents
or for those patients who are
awaiting endoscopy.2 According
to published guidelines, an endoscopy should be performed within
24 hours of suspicion of an active
upper
gastrointestinal
bleed
(GIB). An IV bolus followed by
continuous infusion PPI is recommended for patients who have undergone successful endoscopic
therapy for prevention of rebleeding.2,3,4 The recommended dose
for documented NVUGIB is an 80
mg bolus followed by 8 mg/h continuous infusion for 72 hours. Intravenous pantoprazole continuous infusions generally should not
be continued beyond 72 hours
since the risk of rebleeding after
that time is low.
The use of IV PPIs for stress ulcer
prophylaxis (SUP) is controversial.5,6 Guidelines support the use
of medications for SUP in the following patients: those who are
mechanically ventilated for >48
hours and those with a coagulopathy, renal failure, or admitted to
the intensive care unit (ICU) for
thermal injury or spinal cord injury.7,8,9 The Surviving Sepsis
Campaign provides guidelines to
support the use of histamine-2 receptor antagonists (H2RAs) over
PPIs and sucralfate in all patients
with severe sepsis.10
Currently, there is a lack of evidence to support the use of IV
PPIs as first-line agents for SUP.
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The American Society of
Health-System
Pharmacists
(ASHP) Commission on Therapeutics Guidelines for SUP from
1999 states that there is insufficient evidence to support that IV
PPIs are superior to IV H2RAs
for SUP.8 Furthermore, there are
a lack of comparative data with
IV PPIs and IV H2RAs. While
there is limited evidence to support the use of IV PPIs in SUP,
some clinicians may prefer these
agents based on their ability to
maintain a gastric pH ≥ 4 for
prolonged periods.9,11,12,13 Edelman and colleagues endorse the
following exceptions for the use
of IV PPIs for SUP: thrombocytopenia associated with H2RAs,
refractory gastric pH despite
adequate H2RA therapy, or suspected or documented Helicobacter pylori infection.11
With the low incidence of stress
ulcers and the lack of superiority
of PPIs for this indication, it is
reasonable to utilize the most
cost effective therapy while considering each patient individually.9,12,13 At MUSC, the use of
IV PPIs for SUP is generally
considered inappropriate.
Inappropriate indications for IV
pantoprazole use include SUP,
lower GIB, and GERD, unless
the patient has had documented
treatment failure with first-line
agents (eg, oral pantoprazole,
sucralfate, IV or oral famotidine). Oral therapy should be
considered when patients have
adequate oral intake by mouth or
GI access device without diarrhea, vomiting, malnutrition or
malabsorption.

Inappropriate use of IV PPIs at
other institutions has been identified, and institutional guidelines
and pre-printed order forms have
shown mixed results with regard
to improvement in use.5,9,13-15
Proposed reasons for inappropriate use of IV pantoprazole at
MUSC may include the following:
lack of education about indications, doses, duration of therapy
and alternatives; poor assessment
of eligibility for oral therapy; delay in transition to oral therapy;
failure to document past treatment
failures; and variability in patient
care. The primary objective of
this medication use evaluation
(MUE) was to evaluate the general appropriateness of IV pantoprazole use at MUSC. The secondary objectives were to determine
reasons for inappropriate use of
IV pantoprazole, evaluate the potential cost of inappropriate use,
and provide recommendations for
improvement.
METHODS
Institutional review board (IRB)
approval was obtained for this
MUE. Every order occurrence for
IV pantoprazole in adult patients
from March to October 2008 was
included in the evaluation. Electronic reports were generated that
included the following: patient
demographics (eg, age, gender),
ICU and hospital length of stay,
IV pantoprazole dose, duration of
therapy, enteral and parenteral nutrition orders, endoscopy reports,
GI disease states, cost, and attending physicians. In addition, a retrospective chart review of the
available patient information databases was conducted and the following data was collected: indications, eligibility for oral alterna-
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tive medications, laboratory values, and other data as necessary
for the purposes of the evaluation.
Use of the pre-printed clinician
order form for IV pantoprazole
was noted during data collection.
If patients received IV pantoprazole for probable NVUGIB, lack
of endoscopy within 24 hours was
considered inappropriate use
unless the patient exhibited the
following: coffee ground nasogastric (NG) tube aspirate; guaiacpositive NG tube aspirate; guaiacpostive stools; hematemesis; hematochezia; melena; decrease in
systolic blood pressure of more
than 20 mmHg within 24 hours of
bleed; increase in heart rate of
more than 20 beats per minute
within 24 hours of bleed; or decrease in hemoglobin of more than
2 g/dL within 24 hours of
bleed.4,16 For NVUGIB, the appropriate dose was considered 80
mg bolus followed by 8 mg/h continuous infusion for up to 72
hours. Use of the continuous infusion beyond 72 hours was considered inappropriate.
Doses and duration of therapy
were collected for patients receiving IV pantoprazole intermittent
infusions. Inappropriate use of
intermittent IV infusion was determined largely by eligibility for
oral therapy. Patients were
deemed eligible for oral therapy if
they received either 2 or more
medications or enteral nutrition
by mouth or a GI access device
for at least 24 hours. For those
patients receiving an intermittent
infusion but not eligible for oral
therapy, treatment failure with
other acid-suppressive agents was
determined.
Treatment failure
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was defined as receiving an oral
PPI as an outpatient or a trial of
H2RAs or sucralfate prior to initiation of IV pantoprazole. In
addition, evidence of thrombocytopenia (platelet count <
100,000), GERD with erosive
esophagitis, Helicobacter pylori
infection, and H2RA allergy
were investigated. Any documented inappropriate indications
for the use of IV pantoprazole
outside of the pre-printed order
form were noted, including SUP,
lower GIB, and GERD. Descriptive statistics were performed on the data. Data are
reported as median and interquartile ranges (IQR) because
the patient population was not
normally distributed.
RESULTS
Data were collected on 535 order
occurrences of IV pantoprazole
from March to October 2008
(Table 2). The median age of
the patients was 55 years (range
18-97; IQR 45-66) and 51%

were male. The median hospital
length of stay was 6 days (range
0-185; IQR 3-16), and the median
ICU length of stay was 1 day
(range 0-85; IQR 0-5.5). The preprinted clinician order form was
not used in 22% (n = 117) of order
occurrences.
Thirty-one percent (31%) of orders (n = 165) were continuous
infusions and 69% (n = 370) were
intermittent infusions. Of those
who received continuous infusion,
50% (n = 83) had an endoscopy performed within 24 hours.
Of those who received continuous
infusion and did not have an endoscopy within 24 hours (n = 82),
44% (n = 36) had evidence of
NVUGIB. The median duration
of the continuous infusion was 3
days (range 1-16; IQR 2-4).
Of those who received intermittent therapy, 59% (n = 218) were
eligible for oral therapy. The
most frequent intermittent doses
were 40 mg IV every 12 hours

Table 2: Use of IV Pantoprazole
Continuous Infusion 31% (n = 165)
Median infusion duration: 3 days (range 1-16; IQR 2-4)
Endoscopy performed within 24 hours
Endoscopy not performed within 24 hours
Had evidence of NVUGIB
Intermittent Infusion 69% (n = 370)
40 mg IV every 12 hours

50% (n = 83)
50% (n = 82)
44% (n = 36)
67% (n = 249)

Eligible for oral therapy
Median therapy duration: 4 days (range 1-32; IQR 2-5)
40 mg IV every 24 hours
Eligible for oral therapy
Median therapy duration: 3 days (range 1-17; IQR 2-6)

60% (n = 150)

TOTAL eligible for oral therapy
TOTAL ineligible for oral therapy
On PPI at home OR failed H2RA or sucralfate trial
Had thrombocytopenia
Had GERD with erosive esophagitis
Tested positive for Helicobacter pylori
Had H2RA allergy

59% (n = 218)
41% (n = 152)
71% (n = 108)
30% (n = 46)
3% (n = 5)
3% (n = 4)
1% (n = 2)

27% (n = 99)
58% (n = 57)
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(67%, n = 249) and 40 mg IV, every 24 hours (27%, n = 99). Of those who received 40 mg IV, every 12 hours,
who were eligible for oral therapy (58%, n = 150), the median duration of therapy was 4 days (range 1-32;
IQR 2-5). Of those who received 40 mg IV, every 24 hours, who were eligible for oral therapy (n = 57), median duration of therapy was 3 days (range 1-17; IQR 2-6). Of those who received intermittent therapy and
were not eligible for oral therapy (41%, n = 152), 71% (n = 108) failed previous treatment with first-line therapies, 30% (n = 46) had thrombocytopenia, 3% (n = 5) had GERD with erosive esophagitis, 3% (n = 4) tested
Helicobacter pylori positive and 1% (n = 2) had an H2RA allergy.
Specific documentation of inappropriate indications was noted in 20% (n=106) of order occurrences. Providers listed the following inappropriate indications for IV pantoprazole: 9.5% (n=51) SUP, 2.8% (n=15) GERD,
2.1% (n=11) lower GIB, and 5.4% (n=29) other. Furthermore, all intermittent infusion occurrences in patients
eligible for oral therapy were also considered inappropriate. As stated above, of those who received intermittent therapy, 59% (n=218) were eligible for oral therapy; therefore, 59% of intermittent occurrences were
deemed inappropriate.
Inappropriate use of IV pantoprazole has financial impacts on both the organization and the patient. The estimated cost and savings of an IV to oral conversion of inappropriate pantoprazole use are detailed in Table 3.
Therefore, preventing inappropriate IV pantoprazole intermittent infusion use at MUSC will provide cost savings to the institution and prevent patients from incurring unnecessary expenses during their hospital stay.
Table 3: Costs of Inappropriate Use of IV Pantoprazole
Cost Per Unit ($)
Medication

Pantoprazole
Total

Dosage

Schedule
Hospital

Patient

40 mg

5

99

-----

-----

-----

Q12 hr
Q24 hr
-----

Median
Days of
Inappropriate
Use (n)
4
3
-----

Cost Per Course of
Therapy ($)
Hospital

Patient

40.32
15.12
55.44

792
297
1089

Patients
Eligible
for Oral
Therapy
(n)
150
57
-----

Total Costs ($)
Hospital

Patient

6048
862
6910

118,800
16,929
135,729

CONCLUSIONS
By restricting use of IV pantoprazole to the order form, providers are exposed to appropriate and inappropriate
indications, doses and duration of therapy, as well as alternative choices. The prescribing of continuous infusion pantoprazole was largely appropriate, so further intervention regarding its use is not necessary. However,
the inappropriate use of intermittent infusions, predominantly 40 mg IV every 12 hours or every 24 hours, is
an area where further intervention may be beneficial. Despite a mandatory order form, inappropriate use primarily involved either noncompliance of the form or inadequate review and understanding of the information
on the form. Providers may be more likely to overlook the “clinical practice points” provided because the
doses and indications are listed at the top of the order form. Other factors that may be contributing to inappropriate use include a lack of detailed information on the order form that is necessary to help providers make appropriate decisions and reevaluate their decisions after the initial order.
RECOMMENDATIONS
▪ Ensure that healthcare providers are aware of the pre-printed IV PPI order form through
re-education and promotion.
▪ Changes to the clinician order form will be considered.
▪ Implement a 72 hour automatic stop to all intermittent IV pantoprazole orders.
References available upon request
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Did You Know...
The MUSC Drug Information Center publishes clinically relevant questions and responses that are received in
a Virtual Drug Information (VDI) Database. All MUSC employees have access to VDI. For access, visit
https://www.muschealth.com/vdiSearch/Login.aspx? (links are also available on the Formulary and Drug
Information Web page www.formularyproductions.com/musc).
▪ Use your NetID login and search by keywords or type of question.
▪ Information is only as current as the post date on the entry.
▪ If you do not find what you are looking for, contact the Drug Information Center (2-3896
or druginfo@musc.edu) for assistance.

FORMULARY UPDATE FOR APRIL 2009
In April 2009, The Pharmacy and
Therapeutics Committee approved
the actions listed below. The formulary effective date was May 18,
2009, unless otherwise stated.
ADDITIONS
Zanamavir (Relenza®), an antiretroviral agent similar to oseltamavir, was added to the formulary temporarily as a result of the
Swine Influenza type A (H1N1)
outbreak. This was to allow the
hospital to stock additional antiretroviral agents effective against
the disease in case the outbreak
worsens. Once H1N1 virus is
contained, zanamavir will be removed from the formulary and
oseltamavir will be the sole formulary agent.
Powder for inhalation: 5 mg
Formulary effective date: April 28, 2009

MODIFICATION
In order to increase pharmacy
storage space, it was requested
that the organization simplify the
combination oral contraceptive
options available on formulary.
For hospitalized patients, these
agents are primarily used to control severe uterine bleeding following. Based on utilization data
from the past 2 years, all combination oral contraceptive options
will be removed from the formu-

lary except for Ovcon® 35,
Ovcon® 50, and Lessina™. Hospitalized patients requiring nonformulary combination oral contraceptives will have the option to
bring in their own medication or
the product will be obtained from
one of the ambulatory pharmacies.

CHARTS, GUIDELINES, AND
ORDER FORMS

The following was removed from
the formulary:
▪ Ethinyl estradiol/levonorgestrel

▪

▪

▪

▪
▪
▪
▪

(Portia®)
Ethinyl estradiol/norethindrone
(Junel™ Fe 1.5/30)
Ethinyl estradiol/norgestrel
(Cryselle®)
Ethinyl estradiol/norgestimate
(Sprintec™)
Ethinyl estradiol/levonorgestrel
(Empresse®)
Ethinyl estradiol/norgestimate
(Tri-Sprintec™)

LINE EXTENSIONS
▪ Acetaminophen 160-mg/5-ml oral
suspension, unit-dose cups
▪ Polysaccharide iron complex
(Ferrex® 150; Ferrex® 150 Plus)
capsules

DELETIONS
▪ Antihemophilic factor VIII

(Helixate®) 500-unit vial
▪ Polysaccharide iron complex
(Niferex®; Niferex® 150; Niferex®
PN) capsules

Policy C78: Medication Orders*
was updated with the following:
▪ Use of blue or black ink for
▪

▪
▪

written orders
Inclusion of allergy information on
all medication orders
Specific dates must be listed on an
order when writing future orders
post-op (eg, Post-Op day #1 must
be defined)
Nursing must be notified of any
STAT order that has been placed
Transfer orders expire 24 hours
after the time that they were originally written
Differentiation between manually
written orders and CPOE

Policy C126: Expiration Dating*
was amended so that Appendix A
now summarizes all requirements
for the labeling of medications.
▪ Syringes prepared outside of a
pharmacy clean room expires 1
hour after preparation.
▪ For IV bags prepared outside a
pharmacy clean room, administration must begin within 1 hour of
preparation and expires 12 hours
after administration is initiated.

Policy C117: Medication Labeling* now refers to Policy C126
for expiration date/time requirements for medication labels.
*These policy changes are pending Medical Executive
Committee (MEC) approval.

